Draegerwerk Ag & Co. Kgaa · XETR:DRW8

Draegerwerk Ag & Co. Kgaa — Drägerwerk AG & Co. KGaA — Q1 2023 Earnings Presentation

36 slides from Draegerwerk Ag & Co. Kgaa's earnings presentation, Apr 28, 2023

Slide 1: Capital Markets Presentation Drägerwerk AG & Co. KGaA
Capital Markets Presentation Drägerwerk AG & Co. KGaA April 2023, Lübeck Drägerwerk AGAG © Drägerwerk & Co. KGaA, & Co. 2023 KGaA, 2020
Slide 2: Disclaimer
Disclaimer This presentation does not constitute an offer of securities for sale or a solicitation of an offer to purchase any securities. No money, securities or other consideration is being solicited by this presentation. This presentation contains forward-looking statements regarding the future d
Slide 3: Dräger, The Company, Financials, Outlook
Dräger The Company Financials Outlook Drägerwerk AGAG & Co. KGaA, 2023 © Drägerwerk & Co. KGaA, 2020 3
Slide 4: Dräger products protect, support and save lives
Dräger products protect, lives support and save Drägerwerk AGAG & Co. KGaA, 2023 © Drägerwerk & Co. KGaA, 2020 4
Slide 5: Net sales development
Net sales development Long-term growth COVID-19 Ukraine pandemic war 4.000 3.500 Debt crisis 3.000 Financial Stock- crisis 2.500 market Russian 2.000 Mexican financial crash peso crisis 1.500 crisis 1.000 500 1990 1992 1993 1994 1995 1996 1997 1998 2000 2002 2003 2004 2005 2006 2007 2008 1991 1999 2
Slide 6: Dräger worldwide
Dräger worldwide Net sales, employees and sites 20% ~40% Safety Division 3.0 billion ~60% EUR net sales Medical Division 2022 26% 54% 18% Production, Quality, 14% Logistics & Purchasing 59% 65% Sales & Service 16,219 15.657 Employees inin 11% Mitarbeiter R&D 2022* 2020* 70% 11% Administration Headqu
Slide 7: Markets
Markets Our Customers Hospital Fire services Oil and gas industry Mining Chemical industry Other markets Drägerwerk AGAG & Co. KGaA, 2023 © Drägerwerk & Co. KGaA, 2020 7
Slide 8: Medical Division
Medical Division Hospital wide Intensive Care Operating Room Neonatal Care Solutions Anaesthesiology  Anaesthesia workstations Patient Monitoring & Clinical IT and vaporizers  #1 in Europe and   #2 in the US market  Infinity Acute Care System  Clincal software solutions  Telemetry and IT-solu
Slide 9: Safety Division
Safety Division Fire Service Oil & Gas Chemical Mining Other Markets Breathing Systems  Self-contained Breathing Impairment Check Equipment Appartus for fire fighters  #2 worldwide and       Alcohol- and drug screening #1 in Europe devices  Interlock devices Gas Detection Systems   #1 wor
Slide 10: Medical and safety technology providing long-term growth prospects
Medical and safety technology providing long-term growth prospects Medical division Safety division Attractive growth prospects  Average expected annual market growth for the  Very diversified markets with numerous product and in sizeable markets … global medical equipment market significantly ser
Slide 11: Technology and innovation leadership to drive profitable growth
Technology and innovation leadership to drive profitable growth Strong R&D focus Innovation to enhance future growth (examples)  Approximately 1,800 employees in R&D around the globe.  EUR ~344 million spent for R&D activities in 2022.*  Very close collaboration with customers to develop new and
Slide 12: Exploit growth potentials in developing countries
Exploit growth potentials in developing countries  Focus on the specific needs of customer in developing countries  Capitalize on the significant investments into the Sales & Service infrastructure and specific market Investments in profitable knowledge, especially in our Region AAA and in Central
Slide 13: Service- and consumables business a clear focus of our sales activities
Service- and consumables business a clear focus of our sales activities Further expansion of  Capitalize on large installed base to expand after sales business service and consumables  Focus on combined sale of equipment and after sales contracts business  Expansion of disposable consumables busi
Slide 15: Business development
Business development Dräger Group 5-year view Note: Restructuring charges included in FY EBIT: EUR 10 million in 2016 Dräger Value Added (DVA) = EBIT less cost of capital of average invested capital Drägerwerk AGAG& Co. KGaA, 2023 © Drägerwerk & Co. KGaA, 2020 15
Slide 16: Key figures
Key figures Dräger Group 5-year view 1 Values as of reporting date 2 EBITDA and accordingly EBIT of the last twelve months Drägerwerk AGAG & Co. KGaA, 2023 © Drägerwerk & Co. KGaA, 2020 16
Slide 18: Guidance
Guidance 1 Based on exchange rates at the start of the fiscal year 2022 Drägerwerk AGAG & Co. KGaA, 2023 © Drägerwerk & Co. KGaA, 2020 18
Slide 19: Drägerwerk AG & Co. KGaA, 2023
Drägerwerk AG & Co. KGaA, 2023
Slide 20: Expectation for fiscal year 2023
Expectation for fiscal year 2023 1 Excluding company acquisitions and the capitalization of right-of-use assets pursuant to IFRS 16 Drägerwerk AGAG & Co. KGaA, 2023 © Drägerwerk & Co. KGaA, 2020 20
Slide 21: The Dräger Executive Board
The Dräger Executive Board Stefan Dräger Gert-Hartwig Lescow Rainer Klug Dr. Reiner Piske Anton Schrofner Chairman of the Deputy Chairman of the Executive Board member Executive Board member Executive Board member Executive Board Executive Board; for Safety Division for Sales & Service and for Medic
Slide 22: Shareholder structure
Shareholder structure 10,160,000 common shares (28.4% free float) 8,600,000 preferred shares (100.0% free float) Shareholding* Shareholding* Common shares Dr. Heinrich Dräger GmbH 2.95% 28.38% 23,2% 17.6% 68.67% 59.2% Members of the Dräger family Successors of Dr. Heinrich Dräger Dr. Heinrich Dräger
Slide 23: Business development
Business development Group / Division / Region Drägerwerk AGAG & Co. KGaA, 2023 © Drägerwerk & Co. KGaA, 2020 23
Slide 24: Medical division
Medical division Business development 12M - 5 year view Note: The data, including the quarterly figures, can be downloaded from the Dräger website in .xls-format Drägerwerk AGAG & Co. KGaA, 2023 © Drägerwerk & Co. KGaA, 2020 24
Slide 25: Safety division
Safety division Business development 12M - 5 year view Note: The data, including the quarterly figures, can be downloaded from the Dräger website in .xls-format Drägerwerk AGAG & Co. KGaA, 2023 © Drägerwerk & Co. KGaA, 2020 25
Slide 26: Functional expenses
Functional expenses Group 5 year view 1 Values as of reporting date Drägerwerk AGAG & Co. KGaA, 2023 © Drägerwerk & Co. KGaA, 2020 26
Slide 27: Cash flow statement
Cash flow statement Group 5 year view 1 Change in cash and cash equivalents, i.e. without any effect of exchange rates 2 Value as of reporting date 3 Incl. short-term, highly liquid money market funds Drägerwerk AGAG& Co. KGaA, 2023 © Drägerwerk & Co. KGaA, 2020 27
Slide 30: Simplification of the capital structure: Termination of participation certificates (1 of 2)
Simplification of the capital structure Termination of participation certificates (1 of 2) Distributable result 32% 100% Participation certificates Common & preferred shares Series A, series K, series D 5 Securities 2 Securities 68% Common & preferred shares Drägerwerk AGAG & Co. KGaA, 2023 © Dräger
Slide 31: Simplification of the capital structure: Termination of participation certificates (2 of 2)
Simplification of the capital structure Termination of participation certificates (2 of 2) Termination of participation certificates Earnings per share In 2020, all 831,951 outstanding participation certificates were cancelled Pro forma as of December 2020, assuming full distribution and including d
Slide 32: Innovation share
Innovation share Share on new products and upgrades medical1 . New products Upgrades 45% 41% 40% 37% 36% 35% 30% 30% 28% 26% 25% 24% 20% 32% 20% 32% 25% 23% 15% 21% 10% 18% 15% 5% 5% 5% 4% 5% 2% 3% 0% 2016 2017 2018 2019 2020 2021 2022 1 Launched in the last 3 years; products are regarded as new, if
Slide 33: Sustainablity @ Dräger
Sustainablity @ Dräger  ISS awards Dräger in its ESG Corporate Rating 2022 with the ›Prime‹-Label.  EcoVadis rates Dräger in its 2022 CSR-assessment with the ›Gold‹ status, placing the Company among the best 1% of the industry cluster.  MSCI scores Dräger in its ESG rating 2022 with ›AA‹.  ESG c
Slide 34: Financial calendar 2023
Financial calendar 2023 Dräger publishes preliminary results approximately 2 weeks before the dates of the quarterly reports. Preliminary results for the full year are published in January. - March 9, 2023 Annual Report 2022 Conference call - April 28, 2023 Report for the first three months 2023 Con

Drägerwerk AG & Co. KGaA — Q1 2023 Earnings Presentation on 6ix

Draegerwerk Ag & Co. Kgaa — Drägerwerk AG & Co. KGaA — Q1 2023 Earnings Presentation

Slide 1: Capital Markets Presentation Drägerwerk AG & Co. KGaA

Slide 2: Disclaimer

Slide 3: Dräger, The Company, Financials, Outlook

Slide 4: Dräger products protect, support and save lives

Slide 5: Net sales development

Slide 6: Dräger worldwide

Slide 7: Markets

Slide 8: Medical Division

Slide 9: Safety Division

Slide 10: Medical and safety technology providing long-term growth prospects

Slide 11: Technology and innovation leadership to drive profitable growth

Slide 12: Exploit growth potentials in developing countries

Slide 13: Service- and consumables business a clear focus of our sales activities

Slide 14: Financials

Slide 15: Business development

Slide 16: Key figures

Slide 17: Outlook

Slide 18: Guidance

Slide 19: Drägerwerk AG & Co. KGaA, 2023

Slide 20: Expectation for fiscal year 2023

Slide 21: The Dräger Executive Board

Slide 22: Shareholder structure

Slide 23: Business development

Slide 24: Medical division

Slide 25: Safety division

Slide 26: Functional expenses

Slide 27: Cash flow statement

Slide 28: Balance sheet

Slide 29: Balance sheet

Slide 30: Simplification of the capital structure: Termination of participation certificates (1 of 2)

Slide 31: Simplification of the capital structure: Termination of participation certificates (2 of 2)

Slide 32: Innovation share

Slide 33: Sustainablity @ Dräger

Slide 34: Financial calendar 2023

Slide 35: Contact

Slide 36: Thank you